BRIEF-Gilead Sciences Says European Commission Authorizes Twice-Yearly Yeytuo For HIV Prevention
Reuters
Aug 26
BRIEF-Gilead Sciences Says European Commission Authorizes Twice-Yearly Yeytuo For HIV Prevention
Aug 26 (Reuters) - Gilead Sciences Inc GILD.O:
GILEAD SCIENCES: EUROPEAN COMMISSION AUTHORIZES TWICE-YEARLY YEYTUO (LENACAPAVIR) FOR HIV PREVENTION
GILEAD SCIENCES: LENACAPAVIR TO BE GRANTED 1 EXTRA YEAR OF MARKET PROTECTION IN EU
Source text: [ID:]
Further company coverage: GILD.O
((Reuters.Briefs@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.